ChemDiv’s team of trained and highly experienced scientists is proud to offer unparalleled expertise in developing and accommodating assays for high throughput screening format and designing orthogonal assays for early identification and removal of false positive hits from further costly follow up processes. Not being limited to a third party small molecule libraries for screening and by offering our proprietary focused discovery sub-libraries assembled from the ChemDiv’s ever-growing collection of 1.6 million small molecules, being synthesized based on unique ideas of novel templates, provides tremendous benefits for high throughput screening. Unique design of these sub-libraries provides a very robust way for early mini-SAR analysis for identification and confirmation of hit series, which then become seed templates for hit expansion, hit-to-lead exploration, and medicinal chemistry lead optimization.
A robust screening platform encompassing automated liquid handling and multimode signal detection equipment have been assembled at ChemDiv to be able to provide access to screening assays for multiplicity of targets, such as receptors, enzymes, signaling pathways etc., which play major role in different therapeutics areas (oncology, immunology, CNS, metabolic diseases).
We have assembled a robust screening infrastructure to be able to work with targets of major therapeutics areas. Our technical park of Discovery Division includes:
Biomek FX work station
96/384-well plate readers;
FLIPR-Tetra (Molecular Devices)
Microbeta PLUS 1450 (PerkinElmer),
Victor2V and Victor 3 multimode;
SpectraMax Plus 96/384;
Mach III (Tomtec) 96-well cell harvester;
Beckman and GUAVA 96/384 well format Flow Cytometers.